{"id":"NCT05691712","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes","officialTitle":"A Randomized, Phase 3, Double Blind Trial Comparing the Effect of the Addition of Tirzepatide Versus the Addition of Placebo to Titrated Basal Insulin on Glycemic Control in Chinese Participants With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-02-05","primaryCompletion":"2024-07-01","completion":"2024-07-01","firstPosted":"2023-01-20","resultsPosted":"2025-08-08","lastUpdate":"2025-08-08"},"enrollment":257,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Type 2","Diabetes Mellitus","Glucose Metabolism Disorders","Metabolic Disease","Endocrine System Diseases"],"interventions":[{"type":"DRUG","name":"Tirzepatide","otherNames":["LY3298176"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"5 Milligram (mg) Tirzepatide","type":"EXPERIMENTAL"},{"label":"10 mg Tirzepatide","type":"EXPERIMENTAL"},{"label":"15 mg Tirzepatide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main purpose of this study is to compare the effect of the addition of tirzepatide or placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes.","primaryOutcome":{"measure":"Mean Change From Baseline in HbA1c (Tirzepatide 10 or 15 Milligram [mg])","timeFrame":"Baseline, Week 40","effectByArm":[{"arm":"10 mg Tirzepatide","deltaMin":-26.1,"sd":1.367},{"arm":"15 mg Tirzepatide","deltaMin":-25.9,"sd":1.386},{"arm":"Placebo","deltaMin":-9.96,"sd":1.34}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":25,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":65},"commonTop":["Diarrhoea","Decreased appetite","Upper respiratory tract infection","Lipase increased","Nausea"]}}